Company estimates that the study would be completed by August 2020, Glenmark Pharmaceuticals has initiated Phase-3 clinical trials in India on antiviral drug Favipiravir, for which it received approval from India’s drug regulator DCGI in late April 2020.
Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Clinical trials have commenced and over 10 leading government & private hospitals in India.
Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. The molecule, if commercialised, will be marketed under the brand name ‘FabiFlu’ in India.
The data from these trials will point in a clearer direction with regard to COVID-19 treatment. Company’s effort is to launch a treatment for COVID-19 patients as soon as possible and control the spread of the pandemic. Treatment duration is a maximum of 14 days and the total study duration will be a maximum of 28 days from randomisation.
Also read :
No comments:
Post a Comment